GSE212057 SIRT6 overexpression 2 v 7 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE212057_SIRT6 overexpression_2_v_7_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE212057_SIRT6 overexpression_2_v_7_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE212057_SIRT6 overexpression_2_v_7_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE212057_SIRT6 overexpression_2_v_7_human_up.

Results found

Linked to

 

Label

Description

 

Gene

ral guanine nucleotide dissociation stimulator like 2

Gene

uncharacterized LOC283683

Gene

long intergenic non-protein coding RNA 649

Gene

TPTE pseudogene 1

Gene

zinc finger protein 702, pseudogene

Gene

CTBP1 divergent transcript

Gene

FEZF1 antisense RNA 1

Gene

ZNF667 antisense RNA 1

Gene

CNN3 divergent transcript

Gene

5-hydroxytryptamine receptor 7 pseudogene 1

  • Gene

    ral guanine nucleotide dissociation stimulator like 2


  • Gene

    uncharacterized LOC283683


  • Gene

    long intergenic non-protein coding RNA 649


  • Gene

    TPTE pseudogene 1


  • Gene

    zinc finger protein 702, pseudogene


  • Gene

    CTBP1 divergent transcript


  • Gene

    FEZF1 antisense RNA 1


  • Gene

    ZNF667 antisense RNA 1


  • Gene

    CNN3 divergent transcript


  • Gene

    5-hydroxytryptamine receptor 7 pseudogene 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.